Stop parsing PDFs. Get the API. Request Access

AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Recordati Industria Chimica e Farmaceutica

Investor Presentation • Jul 29, 2015

4056_10-k-afs_2015-07-29_6514bf8c-1565-4a40-a247-9971c0be9248.pdf

Investor Presentation

Open in Viewer

Opens in native device viewer

CONFERENCE CALL – 29JULY 2015

Firsthalf 2015 highlights

  • • Revenue € 539.1million, up 6.2%
  • • EBITDA € 163.9 million or 30.4%of sales, up 15.5%
  • •Operating income (EBIT) € 145.2 million or 26.9% of sales, up 19.2%
  • • Net income € 103.2 million or 19.2%of sales, up 24.3%
  • • Net debt € 139.9 million, a reduction of € 46.2 million as compared to year‐end 2014.

Mainproduct sales

Corporate products including drugs for rare diseases account for 59.3%of revenue

(
l
l
)
i
i
E
m
o
n
u
r
o		 2
0
1
H
1
5		 1
H
2
0
1
4		 h
%
C
a
n
g
e
®
d
(
l
d
)
Z
i
i
i
i
i
a
n
p
e
r
c
a
n
p
n
e		 6
3
9		 5
8
4		 9
4
®
(
)
l
d
l
l
i
i
i
i
i
Z
+
a
n
p
r
e
s
s
e
r
a
n
p
n
e
e
n
a
a
p
r
c		 3
4
3		 3
1
2		 9
9
®
(
l
d
)
U
i
i
r
o
r
e
c
s
o
o
s
n		 3
3
0		 2
8
4		 1
6
1
®
(
)
L
i
i
i
t
t
t
v
a
o
p
a
v
a
s
a
n
z		 1
3
4		 1
2
4		 9
7
h
d
*
O
t
t
t
e
r
c
o
r
p
o
r
a
e
p
r
o
u
c
s		 1
0
1
0		 9
6
2		 4
9
f
d
D
i
r
u
g
s
o
r
r
a
r
e
s
e
a
s
e
s		 7
3
9		 6
0
3		 2
2
6

* Include the OTCcorporate products for an amount of € 28.0 million in 2015 and € 23.8 million in 2014.

Adiversified product portfolio

FirstTotal revenue € 539.1m

Composition of revenue by geography

Solidvolume growth

(
l
l
)
i
i
E
m
o
n
u
r
o		 1
H
2
0
1
5		 2
0
1
H
1
4		 h
C
%
a
n
g
e
l
I
t
a
y		 2
1
1
7		 1
1
9.
7		 (
)
9
5.
F
r
a
n
c
e		 5
5
5		 5
5.
3		 0.
4
G
e
r
m
a
n
y		 4
5
3		 4
0.
5		 1
1.
8
k
T
u
r
e
y		 4
0
6		 3
3.
6		 2
0.
6
U
S.
A		 3
9
8		 2
7.
7		 4
3.
8
S
i
p
a
n		 3
4
8		 3
3.
8		 3.
1
h
d
k
i
i
i
R
C
I
S
U
t
t
u
s
s
a,
o
e
r
c
o
u
n
r
e
s
a
n
r
a
n
e		 3
4
6		 3
9.
3		 (
)
1
1.
9
h
f
N
A
i
t
o
r
r
c
a		 2
3
9		 1
9.
9		 2
0.
0
l
P
t
o
r
u
g
a		 1
9
1		 1
8.
0		 5.
8
h
O
C
E
E
i
t
t
e
r
c
o
u
n
r
e
s		 2
1
5		 1
2.
4		 2
2.
8
h
i
O
W
E
t
t
e
r
u
r
o
p
e
c
o
u
n
r
e
s		 1
3
0		 1
1.
6		 1
2.
2
h
l
l
O
i
i
t
t
t
e
r
n
e
r
n
a
o
n
a
s
a
e
s		 8
8
5		 7
8.
2		 9.
7
O
C
C
S
T
T
A
L
P
H
A
R
M
A
E
U
T
I
A
L		 5
2
0
3		 9
0.
0
4		 6.
2
P
H
A
R
M
A
C
E
U
T
I
C
A
L
C
H
E
M
I
C
A
L
S		 1
8,
8		 1
7.
6		 6.
8
(
l
l
l
l
)
I
i
i
n
o
c
a
c
u
r
r
e
n
c
y,
m
o
n
s		 1
H
2
0
1
5		 2
0
1
H
1
4		 h
%
C
a
n
g
e
i
R
(
)
R
U
B
u
s
s
a		 1,
9
1
8
2		 1,
5
3
9.
9		 2
4
6
k
h
b
d
T
i
i
i
(
)
T
R
Y
r
s
s
s
a
r
u
u
y		 0
1
1
1		 9
4
5		 1
6.
5
U
S.
A
(
)
U
S
D		 4
4
4		 3
7.
9		 1
7.
2

Geographical breakdown of pharmaceutical revenue

Data: First half 2015Pharmaceutical revenue € 520.3m

Firsthalf 2015 results

Furthermargin growth

(
)
l
l
i
i
E
m
o
n
u
r
o		 2
0
1
H
1
5		 1
H
2
0
1
4		 h
%
C
a
n
g
e
R
e
e
n
e
v
u		 3
9
1
5		 0
6
5
7		 6
2
f
G
P
i
t
r
o
s
s
r
o		 3
6
6
8		 3
3
6
6		 9
0
f
%
a
s
o
r
e
v
e
n
u
e		 6
8
0		 6
6
3
&
S
G
A
E
x
p
e
n
s
e
s
f
%
a
s
o
r
e
v
e
n
u
e		 8
2
1
1
3
3
8		 1
7
3
6
3
2
4		 4
9
&
R
D
E
p
e
n
s
e
s
x		 3
7
9		 0
4
7		 (
)
6
8
f
%
a
s
o
r
e
v
e
n
u
e		 0
7		 8
0
(
),
h
O
I
E
t
t
e
r
n
c
o
m
e
x
p
e
n
s
e
n
e		 (
)
1
6		 (
)
0
5		 2
3
2
6
f
%
a
s
o
r
e
v
e
n
u
e		 (
)
0
3		 (
)
0
1
i
O
I
t
p
e
r
a
n
g
n
c
o
m
e		 1
4
5
2		 1
2
1
8		 1
9
2
f
%
a
s
o
r
e
v
e
n
u
e		 2
6
9		 2
0
4
N
I
t
e
n
o
m
e
c		 0
3
2
1		 8
3
0		 2
4
3
f
%
a
s
o
r
e
v
e
n
u
e		 1
9
2		 1
6
4
E
B
I
T
D
A		 1
6
3
9		 1
4
1
9		 1
5
5
f
%
a
s
o
r
e
v
e
n
u
e		 3
0
4		 2
7
9

Firsthalf 2015 results

Operating segments

Financial position and Shareholders' equity

(
)
l
l
i
i
E
m
o
n
r
o
u		 3
0
J
2
0
1
5
n
u		 3
1
2
0
1
D
4
e
c		 h
C
a
n
g
e
f
h
d
h
l
C
i
i
t‐
t
a
s
a
n
s
o
r
e
r
m
n
a
n
c
a
i
t
t
n
v
e
s
m
e
n
s		 1
8
6
8		 1
3
7
0		 4
9
8
k
d
f
d
h
l
B
t
t‐
t
a
n
o
v
e
r
r
a
s
a
n
s
o
r
e
r
m
o
a
n
s		 (
)
0
0
1		 (
)
8
6		 (
)
1
4
d
h
i
i
L
t
o
a
n
s
e
n
o
n
e
e
a
r
u
w
y
–		 (
)
2
9
9		 (
)
2
8
3		 (
)
1
6
d
f
L
t
o
a
n
s
u
e
a
e
r
o
n
e
y
e
a
r
–		 (
)
2
8
6
8		 (
)
2
8
6
2		 (
)
0
6
O
S
O
N
E
T
F
I
N
A
N
C
I
A
L
P
I
T
I
N		 (
)
1
3
9
9		 (
)
1
8
6
0		 4
6
2
'
S
H
A
R
E
H
O
L
D
E
R
S
E
Q
U
I
T
Y		 8
7
4
9		 7
8
7
4		 8
7
4

Financial projections

2015targets

(
l
l
)
i
i
E
m
o
n
u
r
o		 2
0
1
4
l
A
t
c
u
a		 2
0
1
5
T
t
a
r
g
e
s
R
e
v
e
n
u
e		 9
8
7
4		 1
0
4
0
±
,
i
i
O
t
p
e
r
a
n
g
n
c
o
m
e
(
)
E
B
I
T		 2
3
0
1		 2
0
7
±
N
I
t
e
n
c
o
m
e		 1
6
1
2		 1
9
0
±

Company declarations, disclaimers and profile

DECLARATIONBY THE MANAGER RESPONSIBLE FOR PREPARING THE COMPANY'S FINANCIAL REPORTS

The manager responsible for preparing the company's financial reports Fritz Squindo declares, pursuant to paragraph 2 of Article 154‐bis of the Consolidated Law on Finance, that the accounting information contained in this presentation corresponds to the document results, books and accounting records.

Statements contained in this presentation, other than historical facts, are "forward‐looking statements" (as such term is defined in the Private Securities Litigation Reform Act of 1995). These statements are based on currently available information, on current best estimates, and on assumptions believed to be reasonable. This information, these estimates and assumptions may prove to be incomplete or erroneous, and involve numerous risks and uncertainties, beyond the Company's control. Hence, actual results may differ materially from those expressed or implied by such forward‐looking statements.

All mentions and descriptions of Recordati products are intended solely as information on the general nature of the company's activities and are not intendedto indicate the advisability of administering any product in any particular instance.

Recordati, established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271) with a total staff of around 4,000, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations in the main European countries, in Russia, in other Central and Eastern European countries, in Turkey, in the United States of America and in North Africa. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research of new drug entities within the cardiovascular and urogenital therapeutic areas and of treatments for rare diseases. Consolidatedrevenue for 2014 is € 987.4 million, operating income is € 231.0 million and net income is € 161.2 million.

Contact Information RecordatiVia M. Civitali 1 +39 02 48787393 20148

Offices: Investor Relations: Website: S.p.A. Marianne Tatschke www.recordati.com Milano, Italy [email protected]

More from Recordati Industria Chimica e Farmaceutica

Transaction in Own Shares 2026
Jan 5
Transaction in Own Shares 2026
Jan 5
Transaction in Own Shares 2025
Dec 23
Transaction in Own Shares 2025
Dec 23
Share Issue/Capital Change 2025
Dec 16
Transaction in Own Shares 2025
Dec 16
Director's Dealing 2025
Dec 11
Director's Dealing 2025
Dec 10
Director's Dealing 2025
Dec 8
Transaction in Own Shares 2025
Dec 3
View all filings →

Talk to a Data Expert

Have a question? We'll get back to you promptly.